Free Trial
→ Why Some AI Stocks Already Surged Over 300 Percent (From Brownstone Research) (Ad)tc pixel
NASDAQ:KALV

KalVista Pharmaceuticals Q1 2026 Earnings Results & Report

KalVista Pharmaceuticals logo

KalVista Pharmaceuticals missed analyst earnings expectations but beat on revenue in its Q1 2026 results, released May 14, 2026. The company reported EPS of -$0.43 versus the -$0.3763 consensus estimate, while revenue of $40.86 million topped the $39.03 million estimate by $1.84 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

KalVista Pharmaceuticals EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.3763
Beat/Miss
Missed by -$0.0538
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

KalVista Pharmaceuticals Revenue Results

Actual Revenue
$40.86 million
Expected Revenue
$39.03 million
Beat/Miss
Beat by +$1.84 million
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

KalVista Pharmaceuticals' Q1 2026 Quarterly reportQuarterly report
(10-Q)

KalVista Pharmaceuticals Q1 2026 Earnings FAQ

KalVista Pharmaceuticals (NASDAQ:KALV) reported earnings of -$0.43 per share for Q1 2026, missing the consensus estimate of -$0.3763. The report was announced on Thursday, May 14, 2026.

KalVista Pharmaceuticals reported revenue of $40.86 million for Q1 2026, against a consensus estimate of $39.03 million.

KalVista Pharmaceuticals Earnings Headlines

DRI Healthcare Trust Collects $178M for Ekterly Royalty Exit
August 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/dri-healthcare-trust-collects-178m-for-ekterly-royalty-exit-4a18f15a
DRI Healthcare Exercises Put Option for $178M Payout
July 10, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/dri-healthcare-exercises-put-option-for-178m-payout-4c7bd876
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
 |  American Alternative (Ad)
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
June 11, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260610759093/en/chiesi-group-completes-acquisition-of-kalvista-pharmaceuticals/
KalVista’s Sebetralstat Extension Study Completion Sets Up Key Catalyst for KALV Investors
June 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kalvistas-sebetralstat-extension-study-completion-sets-up-key-catalyst-for-kalv-investors?utm_source=marketbeat.com&utm_medium=referral
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
May 31, 2026  |  fool.comhttps://www.fool.com/coverage/filings/2026/05/31/kalvista-s-kalv-chief-development-officer-sells-33-800-shares-for-usd905-000/
See More KalVista Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like KalVista Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your email.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals (NASDAQ:KALV) is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema. These candidates are designed to address unmet needs in rare disease and ophthalmology by improving patient convenience, reducing the burden of disease manifestations and potentially offering long‐lasting therapeutic benefit.

Founded in 2010 and headquartered in Cambridge, England, KalVista also maintains operations in Boston, Massachusetts. The company completed its initial public offering on the Nasdaq exchange in 2015 and has since advanced its pipeline through a combination of in‐house research, strategic collaborations and contract manufacturing partnerships. KalVista’s programs target patient populations in North America, Europe and other markets with significant unmet medical need.

KalVista is led by President and Chief Executive Officer Anna Berkenstock, PhD, who brings extensive experience in drug discovery, development and corporate strategy. The broader leadership team and board of directors draw on deep expertise in rare disease biology, protease chemistry and clinical development to guide the company’s strategic priorities and global growth.

View KalVista Pharmaceuticals Profile
Earnings Tools